- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04328038
Personalized Exercise Oncology (PEXO)
January 30, 2025 updated by: Joachim Wiskemann, University Hospital Heidelberg
Personalized Exercise Oncology (PEXO) - Study
The Goal of the study is to identify trait-homogenous groups of cancer patients in regards to their physical activity associated health literacy.
Based on these Groups, individualized exercise protocols and educative strategies can be developed which may increase the efficacy of the exercise therapy and increases the likelihood that patient get involved in physical activity.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
800
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Heidelberg, Germany, 69120
- Heidelberg University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Mixed Cohort of adult cancer patients undergoing treatment Special Subgroup: Multiple Myeloma Patients
Description
Inclusion Criteria:
- Histologically confirmed cancer diagnosis
- Females and males ≥18 years of age
- Undergoing either chemo-, immune-, radio- or anti-hormonal treatment
- Last surgery more than 6 weeks in the past
- Ability to understand English or German
- Be able to provide and understand informed consent
- Have an Eastern Cooperative Oncology Group (ECOG) Performance Score of ≤ 2
Exclusion Criteria:
- Heart insufficiency > NYHA III (New York Heart Association) or uncertain arrhythmia
- Uncontrolled hypertension
- Severe renal dysfunction (GFR < 30%, Creatinine> 3mg/dl)
- Reduced standing or walking
- Current pregnancy
- Any other evidence in the medical record of an absolute contraindication for exercise
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
USA
Cohort from the USA
|
Patient fill out a survey containing: Demographic Information, medical history, several Questionnaires about Health Literacy, Well Being/HRQoL and Fatigue
|
|
Germany
Cohort from Germany
|
Patient fill out a survey containing: Demographic Information, medical history, several Questionnaires about Health Literacy, Well Being/HRQoL and Fatigue
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Clusters
Time Frame: through study completion, an average of 1 year
|
Identification of different, trait-homogenous patient clusters
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Questionnaire: Physical Activity Associated Health Literacy
Time Frame: through study completion, an average of 1 year
|
To assess physical activity-associated health competence the recently developed and validated questionnaire from Sudeck and Pfeifer (2016) will be used
|
through study completion, an average of 1 year
|
|
Questionnaire: Health Literacy
Time Frame: through study completion, an average of 1 year
|
To assess health-literacy the recently developed and validated questionnaire from Sudeck and Pfeifer (2016) will be used
|
through study completion, an average of 1 year
|
|
Questionnaire: Health Related Quality of Life
Time Frame: through study completion, an average of 1 year
|
Quality of Life will be assessed with the validated 30-item self-assessment questionnaire of the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30, version 3.0).
|
through study completion, an average of 1 year
|
|
Questionnaire: Fatigue
Time Frame: through study completion, an average of 1 year
|
To asses fatigue patients will be asked to complete the 12-item EORTC QLQ-FA12 (FA = fatigue), which is a newly developed questionnaire which has been intensively validated
|
through study completion, an average of 1 year
|
|
Questionnaire: Physical Activity
Time Frame: through study completion, an average of 1 year
|
Patient's level of physical activity will be assessed with the SQUASH Physical Activity Questionnaire.
It includes multiple activities referring to a 'normal' week.
Activity dimensions asked include actively commuting physical activity (walking, cycling), physical activity at work or school, household activities, leisure time activities (sports, walking, gardening, cycling).
|
through study completion, an average of 1 year
|
|
Questionnaire: Emotion Thermometers
Time Frame: through study completion, an average of 1 year
|
Emotion thermometers are four-domain visual-analogue scale including distress, anxiety, depression, and anger.
Each domain is rated on an 11-point (0 to 10) Likert scale
|
through study completion, an average of 1 year
|
|
Questionnaire: Brief Pain Inventory (BPI)
Time Frame: through study completion, an average of 1 year
|
Bone pain will be assessed with the Brief Pain Inventory (BPI).
This is a valid and reliable tool for pain measurement in cancer patients with bone metastases.
It measures both pain severity and pain interference on function
|
through study completion, an average of 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 26, 2018
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
February 1, 2026
Study Registration Dates
First Submitted
March 24, 2020
First Submitted That Met QC Criteria
March 27, 2020
First Posted (Actual)
March 31, 2020
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
January 30, 2025
Last Verified
January 1, 2025
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- HRP-591-PEXO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.